S1 Table. Experimental designs.

|  Group  | Treatment regimen | Sacrifice | N (nfinal)a |
| --- | --- | --- | --- |
| **Effect of CVC in the TG-induced peritonitis model in mice** |
| Non-TG + vehicle control | Days 1–5: vehicle controlb PODay 4: PBS IP | Day 6 | 6 (6) |
| TG + vehicle control  | Days 1–5: vehicle controlb BID PODay 4: 3.85% TG 1 mL IP | Day 6 | 8 (8) |
| TG + CVC 5 mg/kg/day  | Days 1–5: CVC 2.5 mg/kg/dose BID PODay 4: 3.85% TG 1 mL IP | Day 6 | 6 (6) |
| TG + CVC 20 mg/kg/day  | Days 1–5: CVC 10 mg/kg/dose BID PODay 4: 3.85% TG 1 mL IP  | Day 6 | 6 (6) |
| TG + CVC 100 mg/kg/day  | Days 1–5: CVC 50 mg/kg/dose BID PODay 4: 3.85% TG 1 mL IP | Day 6 | 6 (6) |
| TG + CVC 20 mg/kg/day  | Days 1–5: CVC 20 mg/kg/dose QD PODay 4: 3.85% TG 1 mL IP  | Day 6 | 6 (6) |
| TG + DEX 1 mg/kg/day  | Days 1–5: DEX 1 mg/kg/dose QD PODay 4: 3.85% TG 1 mL IP  | Day 6 | 6 (6) |
| **Activity of CVC in a rat model of TAA-induced liver fibrosis and cirrhosis** |
| *Group 1: Early intervention* |
| Vehicle control  | Weeks 0–8: TAA 150 mg/kg 3 times/week IP Weeks 0–8: vehicle controlb QD PO | Week 8 | 8 (8) |
| CVC 30 mg/kg/day  | Weeks 0–8: TAA 150 mg/kg 3 times/week IPWeeks 0–8: CVC 30 mg/kg/dose QD PO | Week 8 | 8 (7) |
| CVC 100 mg/kg/day  | Weeks 0–8: TAA 150 mg/kg 3 times/week IPWeeks 0–8: CVC 100 mg/kg/dose QD PO | Week 8 | 8 (5) |
| *Group 2: Established fibrosis* |
| Vehicle control  | Weeks 0–8: TAA 150 mg/kg 3 times/week IPWeeks 4–8: vehicle controlb QD PO | Week 8 | 8 (6) |
| CVC 30 mg/kg/day  | Weeks 0–8: TAA 150 mg/kg 3 times/week IPWeeks 4–8: CVC 30 mg/kg/dose QD PO | Week 8 | 8 (6) |
| CVC 100 mg/kg/day  | Weeks 0–8: TAA 150 mg/kg 3 times/week IPWeeks 4–8: CVC 100 mg/kg/dose QD PO | Week 8 | 8 (4) |
| *Group 3: Cirrhosis reversal* |
| Vehicle control  | Weeks 0–8: TAA 150 mg/kg 3 times/week IPWeeks 8–12: vehicle controlb QD PO | Week 12 | 8 (7) |
| CVC 30 mg/kg/day  | Weeks 0–8: TAA 150 mg/kg 3 times/week IPWeeks 8–12: CVC 30 mg/kg/dose QD PO | Week 12 | 8 (7) |
| CVC 100 mg/kg/day  | Weeks 0–8: TAA 150 mg/kg 3 times/week IPWeeks 8–12: CVC 100 mg/kg/dose QD PO | Week 12 | 8 (8) |
| ***In vivo* efficacy study of CVC in STAM model of NASH** |
| Vehicle control | Day 2: streptozotocin 200 µg SCWeeks 6­–9: vehicle controlb BID PO  | Week 9 | 9 (6) |
| CVC 20 mg/kg/day  | Day 2: streptozotocin 200 µg SCWeeks 6­–9: CVC 10 mg/kg/dose BID PO | Week 9  | 9 (6) |
| CVC 100 mg/kg/day | Day 2: streptozotocin 200 µg SCWeeks 6­–9: CVC 50 mg/kg/dose BID PO | Week 9  | 9 (6) |
| **Dose-dependent effects of CVC on renal biomarkers and fibrosis in UUO mice** |
| Vehicle control(Sham surgery) | Day 0: sham surgeryDays 0–5: vehicle controlb 10 mL/kg BID PO Day -1–4: PBS IP | Day 5 | 6 (6) |
| Vehicle control (Permanent UUO) | Day 0: permanent UUODays 0–5: vehicle controlb 10 mL/kg BID PO Day -1–4: PBS IP | Day 5 | 9 (9) |
| CVC 7 mg/kg/day  | Day 0: permanent UUODays 0–5: CVC 3.5 mg/kg/dose BID PODay -1–4: PBS IP | Day 5 | 9 (8) |
| CVC 20 mg/kg/day  | Day 0: permanent UUODays 0–5: CVC 10 mg/kg/dose BID PO Day -1–4: PBS IP | Day 5 | 9 (8) |
| CVC 100 mg/kg/day | Day 0: permanent UUODays 0–5: CVC 50 mg/kg/dose BID PO Day -1–4: PBS IP | Day 5 | 9 (0) |
| 1D11 3 mg/kg/day  | Day 0: permanent UUODays 0–5: vehicle controlb 10 mL/kg BID PO Day -1–4: 1D11 3 mg/kg IP  | Day 5 | 9 (9) |

aThe number of animals at the start of the study is indicated, with the number of animals at the end of the study on which analyses were conducted indicated in brackets; bVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80. BID, twice daily; CVC, cenicriviroc; DEX, dexamethasone; IP, intraperitoneal; NASH, non-alcoholic steatohepatitis; PBS, phosphate buffer saline; PO, oral gavage; QD, once daily; SC, subcutaneous; STAM, stelic animal model; TAA, thioacetamide; TG, thioglycollate; UUO, unilateral ureter obstruction.